Islet Cell Transplantation

The Oxford AHSN Diabetes Clinical Network Launch Event, February 2014

Stephen Gough
Islet Transplant Service (Oxford)
Islet v Pancreas
Two different approaches
What are the options available?

• Whole Pancreas Transplantation
  - Simultaneous pancreas + kidney (SPK)
  - Pancreas Transplant Alone (PTA)
  - Pancreas after kidney (PAK)

• Islet Transplantation
  - Islet Transplant Alone (ITA)
  - Islet after kidney (IAK)
  - Simultaneous islet + kidney (SIK)
  - Autotransplantation
History of islet cell transplantation

• 267 allografts, 1990-2000

• 41% some graft function

• 12.4% insulin-independence >1 week

• 8.2% insulin-independence for >1 year
The New England Journal of Medicine

© Copyright, 2000, by the Massachusetts Medical Society

VOLUME 343
JULY 27, 2000
NUMBER 4

ISLET TRANSPLANTATION IN SEVEN PATIENTS WITH TYPE 1 DIABETES MELLITUS USING A GLUCOCORTICOID-FREE IMMUNOSUPPRESSIVE REGIMEN

A.M. James Shapiro, M.B., B.S., Jonathan R.T. Lakey, Ph.D., Edmond A. Ryan, M.D., Gregory S. Korbett, Ph.D., Ellen Toth, M.D., Garth L. Warnock, M.D., Norman M. Kneteman, M.D., and Ray V. Rajotte, Ph.D.
Islet Transplantation in Oxford

Pre-NHS up to 2008

9 Transplants pre-Edmonton Protocol

3 Transplants post-Edmonton Protocol (funded by DUK)

NHS post 2008

Currently 8-10 per annum (~30-40 Across UK)

April 2013 – present, 7 (2+5)
Understanding NICE guidance
Information for people who use NHS services

Transplanting donated pancreatic islet cells for patients with type 1 diabetes

NICE ‘interventional procedures guidance’ advises the NHS on when and how new procedures can be used in clinical practice.

This leaflet is about when and how transplanting donated pancreatic islet cells can be used in the NHS to treat people with type 1 diabetes. It explains guidance (advice) from NICE (the National Institute for Health and Clinical Excellence).

Interventional procedures guidance makes recommendations on the safety of a procedure and how well it works. An interventional procedure is a test, treatment or surgery that involves a cut or puncture of the skin, or an endoscope to look inside the body, or energy sources such as X-rays, heat or ultrasound. The guidance does not cover whether or not the NHS should fund a procedure. Decisions about funding are taken by local NHS bodies.
Islet cell transplantation: why?

To improve the quality of life of people with T1DM who suffer severe, recurrent and potentially life-threatening hypoglycaemia

To improve hypoglycaemia unawareness

? to achieve insulin-independence
Transplantation inclusion criteria

- T1DM, > 18 years of age, > 5 years duration
- Failure to optimise glycaemic control with standard therapy without hypoglycaemia
- Impaired awareness of hypoglycaemia
- Recurrent severe hypoglycaemia, (2 or more episodes within the last 2 years)
Process

• Referral by diabetologist to transplant team to Oxford Centre

• Detailed clinical assessment including exclusion of other causes of hypo

• Discuss/council - risks/benefits/alternatives
Percutaneous transhepatic approach via portal vein, local anaesthetic

Infuse over 10-15 minutes

12 hours bed rest

Home 48-72 hours
Intensive Follow-up

• Metabolic control (Blood glucose 4-6 mmol)
• Immunosuppression (+infection/neoplasia)
• Assessment of graft function
• General medical review
Pancreatic islet transplant activity by centre
(1 April 2008 - 8 January 2012)

- Newc: 9 Routine, 4 Priority
- RF: 6 Routine, 3 Priority
- King's: 3 Routine, 1 Priority
- Oxf: 10 Routine, 4 Priority
- Manc: 2 Routine, 1 Priority
- Edin: 4 Routine, 3 Priority
- UK: 34 Routine, 16 Priority
Hypoglycaemia outcomes
(snap shot of few patients 2008 – 2011)

Impact of islet transplantation on annual hypo rate

(UK 1 year graft survival >85%*)

* Brooks AMSA Diabetic Med 2012; 29 (suppl1) :A15
International Outcome Data

Seventh Annual Report

Prepared by:
CITR Coordinating Center
The EMMES Corporation
Rockville, MD

Sponsored by:
National Institute of Diabetes & Digestive & Kidney Diseases
National Institutes of Health
US Department of Health and Human Services
Bethesda, MD

Additional support from:
The Juvenile Diabetes Research Foundation International
New York, NY

December 30, 2011
## Islet cell transplant outcomes

<table>
<thead>
<tr>
<th></th>
<th>1 year</th>
<th>3 year</th>
<th>5 year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulin independence</td>
<td>50%</td>
<td>35%</td>
<td>25%</td>
</tr>
<tr>
<td>Absence of severe hypoglycaemia</td>
<td>90%</td>
<td>75%</td>
<td>50%</td>
</tr>
</tbody>
</table>

(graft function >0.3ng/ml, 50-80% at 5 years)
Attainment of Metabolic Goals in the Integrated UK Islet Transplant Program With Locally Isolated and Transported Preparations

Figure 2: Kaplan–Meier plots of graft survival up to 36 months posttransplant (n = 20).
Post-Islet Transplant Metabolic Outcomes

Severe hypoglycaemic event / patient / year

Pre-transplant: 23
Post-transplant: 0.56

Annual hypos pre
Annual hypos post

Glycated haemoglobin (HbA1c %)

Pre-transplant: 8.23
Post-transplant: 6.83

One witness who saw the defendant behind the wheel shortly before the accident described him as "looking paranoid"

His vehicle mounted a pavement, struck the boy and his brother, then went through a garden wall, across a garden and into a house in Stirchley.

Leading up to the accident the defendant, who was at the wheel of a Renault, had been driving in an erratic manner and was seen to swerve across lanes ....
Pre-transplant glucose profile
(September 2009)

HbA1c 7.0%
Post-transplant glucose profile

HbA1c 6.0%
January 2014

1st transplant September 2009
Remains off insulin, on Liraglutide 1.2 mg OD
Challenges

- National funding for 100 per year
- Oxford largest centre 8-10 per year
- Most referrals from 2-3 centres
- Post-transplant follow-up, intensive
- Have 1 satellite clinic (Birmingham)
Proposal

• Increase hub and spoke service across TV

• AHSN funded transplant coordinator

• Satellite clinics

• Use of IT, (? Skype follow up in local centre)
Conclusions

Islet cell transplantation

Research to Clinical (NHS) service

NICE Outcome Measures are being achieved

- Prevention of recurrent severe hypoglycaemia
- Attainment of HbA1c <53 mmol/mol (7%)

Need to expand the service
Acknowledgements

Oxford Clinical Team
Rob Crookston
Chitra Ballav
Paul Johnson

Transplant Surgeons/Team

Diabetes on-call team – SpRs

Islet Isolation Team